- $0.45m
- $0.45m
- $2.55m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:55 AM
Brief: Envue Medical Inc - Launches Over-The-Counter Enfit Syringes
Brief: Envue Medical Appoints Veteran David Johnson as Chairman
Brief: Nanovibronix Says Company Is Considering Strategic Alternatives For Legacy Assets
Brief: NanoVibronix Launches “Oscar” Training Aid To Accelerate Envue Adoption And Unlock New Revenue Opportunities
Brief: Nanovibronix Announces Pricing Of $2.0 Million Registered Direct Offering
Brief: Nanovibronix Announces Reverse Stock Split
Brief: NanoVibronix’s ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems
Brief: Nanovibronix Says ENvue Medical Granted US Patent For Pediatric Feeding Tube Guidance System
Brief: NanoVibronix Announces Closing Of $10 Million Public Offering Of Preferred Stock And Warrants
Brief: Nanovibronix Regains Nasdaq Compliance
Brief: Nanovibronix announces reverse stock split
Brief: Nanovibronix Advances Development Of Painshield And Uroshield With Completion Of Nextgen Prototypes
Brief: Nanovibronix Completes Pilot Phase Of Clinical Study Of Uroshield At The University Of Michigan
Brief: Nanovibronix Takes Next Step To Partner With Specialist Urology Company To Expand Sales Of Uroshield In Germany
Brief: Nanovibronix Signs Letter Of Intent With Potential New Distributor
Brief: Nanovibronix Announces Commencement Of Uroshield Clinical Study At The University Of Michigan
Brief: NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
Brief: Nanovibronix Gets Nasdaq Letter On Not Meeting Minimum Bid Price Requirement For Continued Listing